3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Myelodysplastic Syndromes
82
Leukemia, Myeloid, Acute
63
Leukemia, Myelomonocytic, Chronic
31
Leukemia
21
Myeloproliferative Disorders
15
Primary Myelofibrosis
9
Thrombocythemia, Essential
7
Polycythemia Vera
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Blast Crisis
7
Myelodysplastic-Myeloproliferative Diseases
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Recurrence
4
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
4
Leukemia, Myeloid, Accelerated Phase
4
Leukemia, Biphenotypic, Acute
4
Anemia, Refractory, with Excess of Blasts
4
Anemia, Refractory
4
Leukemia, Monocytic, Acute
3
Congenital Abnormalities
3
Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Thrombocytopenia
1
Systemic Mastocytosis With an Associated Hematologic Neoplasm
1
Preleukemia
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Interventions
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Decitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Congenital Bone Marrow Failure Syndromes
×
Decitabine
×
Myeloid
×
Clear all
NCT05796570
2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2
Recruiting
37 enrolled